After prostate surgery
PSA after prostatectomy: understand the result before assuming recurrence or reassurance
After radical prostatectomy, PSA is expected to fall to a very low or undetectable range because most PSA-producing prostate tissue has been removed. The exact laboratory wording, timing of the first test, assay sensitivity, pathology, and trend determine what a detectable result means. One decimal place can change the emotional reaction, but the clinical plan should be based on confirmed values and treatment-specific definitions.
Medical review
Medically reviewed by Domenico Savatta, MD, FACS, Innovative Urology.
Last reviewed: July 10, 2026
Review focus: clinical safety, source quality, urgent warning signs, and appointment usefulness.
Quick answer
A detectable PSA after prostatectomy does not answer every recurrence question by itself. The urologist reviews when the blood was drawn, whether the value is confirmed and rising, the laboratory assay, surgical pathology, margin and lymph-node findings, prior PSA pattern, and overall health. Biochemical recurrence is commonly defined using a confirmed PSA threshold after surgery, but clinicians may discuss evaluation before that threshold when an ultrasensitive PSA is rising or pathology is high risk. Do not compare a post-prostatectomy result with age-based screening ranges used for men who still have a prostate.
Read the laboratory report before reading the internet
Laboratories report PSA with different lower limits and decimal precision. 'Less than' a value is not the same as a measured value at that threshold. Ultrasensitive assays can detect tiny changes, but very small fluctuations may not represent a clinically meaningful rise.
Use the same laboratory when practical and compare dated results in order. Ask whether the clinician is using an ultrasensitive trend for early planning or a formal biochemical-recurrence definition for treatment decisions.
Pathology changes what the PSA trend means
The prostatectomy report includes grade group, tumor extent, surgical margins, seminal-vesicle involvement, lymph-node findings, and pathologic stage. These findings help estimate the chance that a rising PSA reflects local microscopic disease, disease outside the prostate bed, or a pattern that needs more information.
Bring the complete report rather than a summary that only says margins were positive or negative. A positive margin is not the same as proven recurrence, and a negative margin does not make a confirmed rise irrelevant.
Doubling time is useful only with enough reliable points
PSA doubling time describes how quickly the value rises. It can contribute to risk assessment, but a calculation based on tiny values, short intervals, different laboratories, or too few tests can be unstable. The number should support clinical judgment rather than replace it.
Ask which values were included, whether the interval is long enough, and how the result changes imaging or treatment timing. A calculator cannot decide whether salvage radiation, systemic therapy, or observation is appropriate.
Imaging and salvage treatment are timing decisions
PSMA PET can locate recurrent prostate cancer in some patients, but detection varies with PSA level and disease biology. A negative scan at a low PSA does not prove that no microscopic disease exists. Imaging should answer a treatment-planning question.
When PSA is confirmed and rising, ask whether a radiation-oncology consultation should occur before waiting for a higher number. The discussion may include the prostate bed, pelvic nodes, hormone therapy, side effects, continence, erectile function, and the evidence for treating at lower PSA levels.
Post-prostatectomy PSA questions by result pattern
| Pattern | What to clarify | Possible discussion |
|---|---|---|
| Undetectable or very low and stable | Assay limit, monitoring interval, pathology risk | Continue scheduled surveillance |
| Low detectable single result | Timing, assay precision, prior value, repeat date | Confirm before labeling a trend |
| Confirmed rising values | Doubling time, pathology, margin and node status | Imaging and radiation-oncology discussion may be considered |
| Persistent PSA soon after surgery | Whether PSA ever became undetectable and whether residual or metastatic disease is suspected | Earlier multidisciplinary evaluation |
Related decision guides
PSMA PET scan for prostate cancer
Understand what the scan can and cannot show at different PSA levels.
Prostate cancer second opinion
Organize pathology, PSA trend, imaging, and treatment questions for another specialist.
Prostate cancer survivorship
Connect recurrence surveillance with continence, sexual function, and long-term recovery.
Questions to bring to the visit
What should PSA be after prostatectomy?
PSA is expected to fall to a very low or undetectable range after the prostate is removed. Interpret the value using the laboratory's assay, timing, pathology, and trend.
Does one detectable PSA result mean recurrence?
Not necessarily. A low detectable result may need confirmation. The pattern, timing, pathology, and whether PSA ever became undetectable matter.
How is biochemical recurrence defined after surgery?
Clinical guidelines commonly use a confirmed PSA threshold after prostatectomy, but evaluation may begin earlier when ultrasensitive PSA is persistently rising or pathology is high risk.
When is PSA doubling time reliable?
It is more useful when calculated from enough reliable values over an adequate interval. Tiny changes or mixed laboratories can make the estimate unstable.
When should PSMA PET or radiation oncology be discussed?
Discuss them when PSA is confirmed and rising, especially when pathology raises risk. Imaging sensitivity and the benefit of earlier salvage planning are part of the timing decision.
New Jersey appointment path
Bring the operative pathology and every dated PSA result
Start with the practice directly. Do not send sensitive medical details through public forms; the office can move the conversation into the right intake process.